Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

The University of Alabama at Birmingham

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Metastatic Colon Cancer

Treatments: Drug: [89Zr]Panitumumab PET-MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT03764137

300002089

Details and patient eligibility

About

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be at least 19 years of age.
• Diagnosis of colon cancer
• Scheduled to undergo surgical resection

Exclusion criteria

• Inability to provide informed consent
• Pregnancy
• Inability to lie still for the imaging study
• Weight over 350 lbs., due to the scanner bore size
• Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
• Inability to receive Omnipaque (iohexol) iodinated contrast
• Inability to receive glucagon
• Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
• Allergy to contrast imaging agents
• Finding or suspicion of distant metastases on CT

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

[89Zr]Panitumumab-PET/MRI patients

Experimental group

Description:

All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.

Treatment:

Drug: [89Zr]Panitumumab PET-MRI